POLARIX was a landmark phase III study that assessed the addition of PV to R-CHP (Rituximab, Cyclophosphamide, Doxorubicin, Prednisone) in the front line setting for DLBCL and compared it to R-CHOP [90]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.